Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS S/AS01E (0.5 mL Dose) to RTS S/AS02D (0.5 mL Dose) Administered IM According to a 0 1 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years .

Next Previous
X
Search
Trial Profile

Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS S/AS01E (0.5 mL Dose) to RTS S/AS02D (0.5 mL Dose) Administered IM According to a 0 1 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years .

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 257049 (Primary) ; AS01E; AS02
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GSK

    • Most Recent Events

    • 26 Apr 2008 Status changed from in progress to completed.
    • 23 Apr 2008 Actual patient number (180) added as reported by ClinicalTrials.gov.
    • 13 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top